Department of Clinical Chemistry, Maastricht University Medical Centre, Maastricht, The Netherlands.
Eur J Vasc Endovasc Surg. 2011 Nov;42(5):563-70. doi: 10.1016/j.ejvs.2011.07.019. Epub 2011 Aug 16.
The aim of the study is to investigate the differential expression of proteins in serum of abdominal aortic aneurysm (AAA) patients in relation to aneurysm size (D(max)) and progression.
Two-dimensional differential in-gel electrophoresis (2D-DIGE) together with tandem mass spectrometry (MS/MS) was used to analyse the serum proteome from patients with small (D(max) 30-54 mm) AAA, either stable (increase D(max) <5 mm year⁻¹; n = 8) or progressive (increase D(max) ≥5 mm year⁻¹; n = 8), and large (D(max) ≥ 55 mm; n = 8) AAA. The identified proteins were quantitatively validated in a larger population (n = 80).
Several proteins were differentially expressed in serum of small stable, small progressive and large AAA. Three validated proteins (immunoglobulin G (IgG), α1-antitrypsin (α1-AT) and Factor XII activity) showed strong correlation with D(max). Size combined with either Factor XII activity or α1-antitrypsin had minimal effect on the prognostic value in predicting aneurysm progression compared with size alone (area under the curve (AUC), 0.85; 95% confidence interval (CI), 0.73-0.97; p < 0.001 and AUC, 0.85; 95% CI, 0.72-0.98; p < 0.001 vs. AUC, 0.83; 95% CI, 0.71-0.96; p < 0.001, respectively).
The present study indicates that both Factor XII and α1-antitrypsin are found in increased amounts in the serum of patients with expanding AAA. However, combination of either Factor XII or α1-antitrypsin with aneurysm diameter had little effect on prediction of aneurysm progression versus diameter alone.
本研究旨在探讨与腹主动脉瘤(AAA)患者的瘤体大小(D(max))和进展相关的血清蛋白的差异表达。
采用二维差异凝胶电泳(2D-DIGE)联合串联质谱(MS/MS)分析小(D(max) 30-54mm)AAA 患者血清蛋白质组,小 AAA 患者稳定(D(max)增加<5mm/年;n=8)或进展(D(max)增加≥5mm/年;n=8),以及大 AAA(D(max)≥55mm;n=8)。在更大的人群(n=80)中定量验证了鉴定出的蛋白。
小稳定、小进展和大 AAA 患者血清中存在一些差异表达的蛋白。三种验证的蛋白(免疫球蛋白 G(IgG)、α1-抗胰蛋白酶(α1-AT)和凝血因子 XII 活性)与 D(max)具有很强的相关性。与单纯瘤体大小相比,大小联合凝血因子 XII 活性或α1-抗胰蛋白酶对预测动脉瘤进展的预后价值影响不大(曲线下面积(AUC),0.85;95%置信区间(CI),0.73-0.97;p<0.001 和 AUC,0.85;95%CI,0.72-0.98;p<0.001 分别 vs. AUC,0.83;95%CI,0.71-0.96;p<0.001)。
本研究表明,凝血因子 XII 和α1-抗胰蛋白酶在扩张性 AAA 患者的血清中含量均增加。然而,与单纯瘤体直径相比,凝血因子 XII 或α1-抗胰蛋白酶与瘤体直径联合对预测动脉瘤进展的影响很小。